Literature DB >> 22649203

Gadolinium compounds signaling through TLR4 and TLR7 in normal human macrophages: establishment of a proinflammatory phenotype and implications for the pathogenesis of nephrogenic systemic fibrosis.

Peter J Wermuth1, Sergio A Jimenez.   

Abstract

Nephrogenic systemic sibrosis is a progressive disorder occurring in some renal insufficiency patients exposed to gadolinium-based contrast agents (GdBCA). Previous studies demonstrated that the GdBCA Omniscan upregulated several innate immunity pathways in normal differentiated human macrophages, induced rapid nuclear localization of the transcription factor NF-κB, and increased the expression and production of numerous profibrotic/proinflammatory cytokines, chemokines, and growth factors. To further examine GdBCA stimulation of the innate immune system, cultured human embryonic kidney 293 cells expressing one of seven different human TLRs or one of two human nucleotide-binding oligomerization domain-like receptors were exposed in vitro for 24 h to various GdBCA. The signaling activity of each compound was evaluated by its ability to activate an NF-κB-inducible reporter gene. Omniscan and gadodiamide induced strong TLR4- and TLR7-mediated reporter gene activation. The other Gd compounds examined failed to induce reporter gene activation. TLR pathway inhibition using chloroquine or an inhibitor of IL-1R-associated kinases 1 and 4 in normal differentiated human macrophages abrogated Omniscan-induced gene expression. Omniscan and gadodiamide signaling via TLRs 4 and 7 resulted in increased production and expression of numerous proinflammatory/profibrotic cytokines, chemokines, and growth factors, including CXCL10, CCL2, CCL8, CXCL12, IL-4, IL-6, TGF-β, and vascular endothelial growth factor. These observations suggest that TLR activation by environmental stimuli may participate in the pathogenesis of nephrogenic systemic fibrosis and of other fibrotic disorders including systemic sclerosis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22649203      PMCID: PMC3381979          DOI: 10.4049/jimmunol.1103099

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  48 in total

1.  Safety of intravenous gadolinium (Gd-BOPTA) infusion in patients with renal insufficiency.

Authors:  R R Townsend; D L Cohen; R Katholi; S K Swan; B E Davies; K Bensel; L Lambrecht; J Parker
Journal:  Am J Kidney Dis       Date:  2000-12       Impact factor: 8.860

2.  Proteomic analysis identification of a pattern of shared alterations in the secretome of dermal fibroblasts from systemic sclerosis and nephrogenic systemic fibrosis.

Authors:  Francesco Del Galdo; M Alexander Shaw; Sergio A Jimenez
Journal:  Am J Pathol       Date:  2010-08-19       Impact factor: 4.307

3.  Type I interferon system activation and association with disease manifestations in systemic sclerosis.

Authors:  Maija-Leena Eloranta; Karin Franck-Larsson; Tanja Lövgren; Sebastian Kalamajski; Anders Rönnblom; Kristofer Rubin; Gunnar V Alm; Lars Rönnblom
Journal:  Ann Rheum Dis       Date:  2010-05-14       Impact factor: 19.103

4.  Stimulation of fibroblast proliferation by insoluble gadolinium salts.

Authors:  Katherine Bleavins; Patricia Perone; Madhav Naik; Muneeb Rehman; Muhammad N Aslam; Michael K Dame; Sasha Meshinchi; Narasimharao Bhagavathula; James Varani
Journal:  Biol Trace Elem Res       Date:  2011-09-01       Impact factor: 3.738

5.  Responses of human skin in organ culture and human skin fibroblasts to a gadolinium-based MRI contrast agent: comparison of skin from patients with end-stage renal disease and skin from healthy subjects.

Authors:  Marissa DaSilva; Monica O'Brien Deming; Suzanne E G Fligiel; Michael K Dame; Kent J Johnson; Richard D Swartz; James Varani
Journal:  Invest Radiol       Date:  2010-11       Impact factor: 6.016

Review 6.  Toll-like receptors in autoimmunity.

Authors:  Maria Fischer; Marc Ehlers
Journal:  Ann N Y Acad Sci       Date:  2008-11       Impact factor: 5.691

7.  Mechanism of NSF: New evidence challenging the prevailing theory.

Authors:  Ben B Newton; Sergio A Jimenez
Journal:  J Magn Reson Imaging       Date:  2009-12       Impact factor: 4.813

Review 8.  Innate immunity and inflammation in systemic sclerosis.

Authors:  Robert Lafyatis; Michael York
Journal:  Curr Opin Rheumatol       Date:  2009-11       Impact factor: 5.006

9.  Gadodiamide contrast agent 'activates' fibroblasts: a possible cause of nephrogenic systemic fibrosis.

Authors:  M Edward; J A Quinn; S Mukherjee; M-B V Jensen; A G Jardine; P B Mark; A D Burden
Journal:  J Pathol       Date:  2008-04       Impact factor: 7.996

10.  Toll-like receptor 3 upregulation by type I interferon in healthy and scleroderma dermal fibroblasts.

Authors:  Sandeep K Agarwal; Minghua Wu; Christopher K Livingston; Donald H Parks; Maureen D Mayes; Frank C Arnett; Filemon K Tan
Journal:  Arthritis Res Ther       Date:  2011-01-11       Impact factor: 5.156

View more
  13 in total

Review 1.  Role of innate immune system in systemic sclerosis.

Authors:  Nicola Fullard; Steven O'Reilly
Journal:  Semin Immunopathol       Date:  2015-07-10       Impact factor: 9.623

2.  Induction of a type I interferon signature in normal human monocytes by gadolinium-based contrast agents: comparison of linear and macrocyclic agents.

Authors:  P J Wermuth; S A Jimenez
Journal:  Clin Exp Immunol       Date:  2014-01       Impact factor: 4.330

Review 3.  TLR2 and TLR4 in autoimmune diseases: a comprehensive review.

Authors:  Yu Liu; Heng Yin; Ming Zhao; Qianjin Lu
Journal:  Clin Rev Allergy Immunol       Date:  2014-10       Impact factor: 8.667

Review 4.  Emerging roles of innate immune signaling and toll-like receptors in fibrosis and systemic sclerosis.

Authors:  Swati Bhattacharyya; John Varga
Journal:  Curr Rheumatol Rep       Date:  2015-01       Impact factor: 4.592

Review 5.  Gadolinium deposition and the potential for toxicological sequelae - A literature review of issues surrounding gadolinium-based contrast agents.

Authors:  Kerry A Layne; Paul I Dargan; John R H Archer; David M Wood
Journal:  Br J Clin Pharmacol       Date:  2018-08-17       Impact factor: 4.335

6.  Gadolinium-based compounds induce NLRP3-dependent IL-1β production and peritoneal inflammation.

Authors:  Christian Schmidt-Lauber; Lukas Bossaller; Hani H Abujudeh; Gregory I Vladimer; Anette Christ; Katherine A Fitzgerald; Eicke Latz; Ellen M Gravallese; Ann Marshak-Rothstein; Jonathan Kay
Journal:  Ann Rheum Dis       Date:  2014-06-09       Impact factor: 19.103

7.  Surface interactions with compartmentalized cellular phosphates explain rare earth oxide nanoparticle hazard and provide opportunities for safer design.

Authors:  Ruibin Li; Zhaoxia Ji; Chong Hyun Chang; Darren R Dunphy; Xiaoming Cai; Huan Meng; Haiyuan Zhang; Bingbing Sun; Xiang Wang; Juyao Dong; Sijie Lin; Meiying Wang; Yu-Pei Liao; C Jeffrey Brinker; Andre Nel; Tian Xia
Journal:  ACS Nano       Date:  2014-01-26       Impact factor: 15.881

8.  Microbial TLR Agonists and Humoral Immunopathogenesis in HIV Disease.

Authors:  Xiaocong Yu; Zihai Li; Zhenxian Zhou; J Michael Kilby; Wei Jiang
Journal:  Epidemiology (Sunnyvale)       Date:  2013-02-02

9.  Practical dynamic contrast enhanced MRI in small animal models of cancer: data acquisition, data analysis, and interpretation.

Authors:  Stephanie L Barnes; Jennifer G Whisenant; Mary E Loveless; Thomas E Yankeelov
Journal:  Pharmaceutics       Date:  2012       Impact factor: 6.321

10.  Effects of Gadolinium-Based Contrast Agents on Thyroid Hormone Receptor Action and Thyroid Hormone-Induced Cerebellar Purkinje Cell Morphogenesis.

Authors:  Winda Ariyani; Toshiharu Iwasaki; Wataru Miyazaki; Erdene Khongorzul; Takahito Nakajima; Satomi Kameo; Hiroshi Koyama; Yoshito Tsushima; Noriyuki Koibuchi
Journal:  Front Endocrinol (Lausanne)       Date:  2016-08-26       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.